| Literature DB >> 7995984 |
R Edelman1, C O Tacket, S S Wasserman, D W Vaughn, K H Eckels, D R Dubois, P L Summers, C H Hoke.
Abstract
A dengue-1 candidate vaccine (45AZ5), previously found to be underattenuated in 2 volunteers, was further attenuated by passage in primary dog kidney (PDK) cell cultures. New candidate vaccines prepared from three levels of PDK-passaged virus, PDK-10, PDK-20, and PDK-27, were each injected into 9 or 10 volunteers. There was a significant, progressive decline in viremia, clinical illness, and hematologic changes from low to high PDK cell passage level. PDK-20 infected all 10 vaccinees and induced viremia in 5, transient fever in 3, symptoms that resulted in curtailed activities for < or = 1 day in 4, and neutralizing antibody in all 10, which persisted for > or = 1 year in 5 of 8 vaccinees tested. Progressive passage in PDK cell culture progressively attenuates vaccine candidate strain 45AZ5 for humans. Because passage level PDK-20 may be suitable for healthy adults at high risk of dengue fever, additional clinical trials of this strain are warranted.Entities:
Mesh：
Substances：
Year: 1994 PMID： 7995984 DOI： 10.1093/infdis/170.6.1448
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226